442 related articles for article (PubMed ID: 19251818)
21. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
[TBL] [Abstract][Full Text] [Related]
22. Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches.
Gao J; Shi Z; Zhu S; Li GQ; Yan R; Yao M
J Ethnopharmacol; 2013 Jan; 145(2):566-72. PubMed ID: 23207062
[TBL] [Abstract][Full Text] [Related]
23. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
[TBL] [Abstract][Full Text] [Related]
24. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.
Patel CG; Zhang J; Li L; Gooding L; Croop R; Li T; Boulton DW
J Clin Pharmacol; 2010 Oct; 50(10):1211-6. PubMed ID: 20150522
[No Abstract] [Full Text] [Related]
25. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
[TBL] [Abstract][Full Text] [Related]
26. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Wang A; Dorso C; Kopcho L; Locke G; Langish R; Harstad E; Shipkova P; Marcinkeviciene J; Hamann L; Kirby MS
BMC Pharmacol; 2012 Apr; 12():2. PubMed ID: 22475049
[TBL] [Abstract][Full Text] [Related]
27. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.
Kim MS; Wang S; Shen Z; Kochansky CJ; Strauss JR; Franklin RB; Vincent SH
Drug Metab Dispos; 2004 Sep; 32(9):909-14. PubMed ID: 15319330
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic study of saxagliptin in healthy Chinese subjects.
Li H; Yang L; Tou CK; Patel CG; Zhao J
Clin Drug Investig; 2012 Jul; 32(7):465-73. PubMed ID: 22668067
[TBL] [Abstract][Full Text] [Related]
30. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.
Mason RP; Jacob RF; Kubant R; Ciszewski A; Corbalan JJ; Malinski T
J Cardiovasc Pharmacol; 2012 Nov; 60(5):467-73. PubMed ID: 22932707
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.
Singh R; Chen IW; Jin L; Silva MV; Arison BH; Lin JH; Wong BK
Drug Metab Dispos; 2001 Dec; 29(12):1578-87. PubMed ID: 11717177
[TBL] [Abstract][Full Text] [Related]
32. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
33. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Borja-Hart NL; Whalen KL
Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
[TBL] [Abstract][Full Text] [Related]
34. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
[TBL] [Abstract][Full Text] [Related]
35. Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor.
Liederer BM; Berezhkovskiy LM; Dean BJ; Dinkel V; Peng J; Merchant M; Plise EG; Wong H; Liu X
Xenobiotica; 2011 Apr; 41(4):327-39. PubMed ID: 21182395
[TBL] [Abstract][Full Text] [Related]
36. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
[TBL] [Abstract][Full Text] [Related]
37. ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.
Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Takakura S; Mutoh S
Acta Diabetol; 2010 Mar; 47(1):43-8. PubMed ID: 19238312
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of picumast after administration of 14C-picumast dihydrochloride in dogs, rats, rabbits and monkeys.
Schaumann W; Besenfelder E; Boehm E; Neubert P; Roesch A; Sterz H
Arzneimittelforschung; 1989 Oct; 39(10A):1321-7. PubMed ID: 2576356
[TBL] [Abstract][Full Text] [Related]
39. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
Upreti VV; Boulton DW; Li L; Ching A; Su H; Lacreta FP; Patel CG
Br J Clin Pharmacol; 2011 Jul; 72(1):92-102. PubMed ID: 21651615
[TBL] [Abstract][Full Text] [Related]
40. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
